POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
ISSCR 2020
06.30.2020
ISSCR 2020 Virtual
A Single IV Dose of Plinabulin Induces Sustained Mobilization of CD34+ Cells in Humans Through A Mechanism of Action Independent From G-CSF or CXCR4 and Without Causing Bone Pain or Thrombocytopenia
American Association for Cancer Research Annual Meeting (2020)
06.23.2020
American Association for Cancer Research (AACR) Virtual Annual Meeting (2020)
Plinabulin, a Microtubule Destabilizing Agent, Improves Tumor Control by Enhancing Dendritic Cell Maturation and CD8 T Cell Infiltration in Combination with Immunoradiotherapy
American Society of Clinical Oncology (ASCO) Virtual Scientific Program (2020)
05.30.2020
American Society of Clinical Oncology (ASCO) Virtual Scientific Program (2020)
Head-to-Head Comparison of the Non-G-CSF Small Molecule Single Agent (SA) Plinabulin with SA Pegfilgrastim for the Prevention of Docetaxel Chemotherapy (Chemo)-Induced Neutropenia (CIN) in the PROTECTIVE-1 Trial
NCCN 2020
03.20.2020
National Comprehensive CancerNetwork (NCCN) Annual Conference (2020)
Plinabulin, a Potent Inducer of Haptoglobin Production for the Prevention of Tissue Iron Overload in Patients Receiving Blood Transfusions Chronically
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
A phase I trial of plinabulinin combination with nivolumaband ipilimumabin patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
06.2021
American Society of Clinical Oncology (ASCO) Annual Meeting (2021)
Chemotherapy Induced Profound Neutropenia (PN) in Patients (pts) with Breast Cancer (BC) after chemotherapy and Plinabulin (Plin) plus Pegfilgrastim(Peg) Combination versus (vs) Peg Alone. Final Phase 3 Results from PROTECTIVE-2
(BPI-2358-106)
PUBLICATIONS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Clinical Cancer Research (2010) 16:5892-5899
12.01.2010
Clinical Cancer Research (2010) 16:5892-5899
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas